home / stock / gene / gene news

GENE News and Press, Genetic Technologies Ltd From 10/13/22

Stock Information
Company Name: Genetic Technologies Ltd
Stock Symbol: GENE
Market: NASDAQ
Website: gtglabs.com
Menu
GENE GENE Quote GENE Short GENE News GENE Articles GENE Message Board
Get GENE Alerts

News, Short Squeeze, Breakout and More Instantly...
GENE - Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / October 13, 2022 / RedChip Companies will air a new interview with Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) ("Company", "GTG"), a global leader in genomics-based tests in health, wellness, and serious disease, on The RedChip Money Report® on Bloombe...
GENE - Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer

MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the recent publication of a ...

GENE - Genetic Technologies Provides Update on US Operations and Payer Engagement

MELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”, “GENE”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to...

GENE - GENE Momentum building - a year in review

MELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results ...
GENE - Gene achieves key milestones and growth

MELBOURNE, Australia, July 28, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease provides its cashflow results for the quarter ended J...

GENE - Higher cardiovascular health may partially offset increased genetic risk for stroke

Research Highlights: A new analysis of a long-term, community-based study has found that maintaining optimal cardiovascular health by following the American Heart Association’s Life’s Simple Seven (LS7) protected people from stroke, regardless of their genetics. The researc...

GENE - GeneType launches Multi-Test in Obstetrics clinics with more than 1,000 referring primary care physicians

MELBOURNE, Australia, July 18, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that we are partnering with ...
GENE - Genetic acquires AffinityDNA to bolster direct-to-consumer business

Genetic Technologies ( NASDAQ: GENE ) completed the acquisition of the direct-to-consumer eCommerce business and distribution rights linked with AffinityDNA. Under the deal, which was announced in May, GENE acquired all AffinityDNA's assets (including web...

GENE - Completion of AffinityDNA Acquisition expanding global direct-to-consumer business

MELBOURNE, Australia, July 14, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that it has completed the ac...

GENE - Longeveron, Adverum top healthcare gainers; while DiaMedica, CytomX lead losers' pack

Gainers: Longeveron ( LGVN ) +16% . Adverum Biotechnologies ( ADVM ) +13% . 89bio ( ETNB ) +12% . Mainz Biomed ( MYNZ ) +11% . Shineco ( SISI ) +8% . Losers: DiaMedica Therapeutics ( DMAC ) -41% . Cytom...
Previous 10 Next 10